Despite initial enthusiasm, different classes of existing cardiovascular medication including: statins, platelet aggregation inhibitors, beta blockers and ACE inhibitors may improve survival regarding overall cardiovascular risk, but they have not shown any significant impact on AAA disease progression in randomised trials. The gene discussed is ACE; the disease is triple-A syndrome.